Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 April 2020
News
Human
Pharmacovigilance
Referrals
PRAC concludes Picato’s risks are greater than its benefits
EMA’s safety committee (PRAC) has confirmed that Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, may increase the risk of skin cancer and concluded that the risks of the medicine outweigh its benefits.
The conclusions are based on a review of all available data on the risk of skin cancer in patients using Picato, including results of a study comparing Picato with imiquimod, another medicine for actinic keratosis. The study showed a higher occurrence of skin cancers, especially squamous cell carcinoma, in areas of skin treated with Picato than in areas treated with imiquimod.
The marketing authorisation for Picato was withdrawn in February 2020.
More information is available below.
Agenda
PRAC recommendation
Article-20 referral : EMA review of Picato concludes medicine’s risks outweigh its benefits
PRAC statistics: April 2020
Glossary:
- Safety signal assessments. A safety signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. More information can be found under Signal management.
- Periodic safety update reports, abbreviated as PSURs, are reports prepared by the marketing authorisation holder to describe the worldwide safety experience with a medicine in a defined period after its authorisation. PSURs for medicinal products that contain the same active substance or the same combination of active substances, but have different marketing authorisations and are authorised in different EU Member States, are jointly assessed in a single assessment procedure. More information can be found under Periodic safety update reports: questions and answers.
- Risk management plans, abbreviated as RMPs, are detailed descriptions of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicines. Companies are required to submit an RMP to EMA when applying for a marketing authorisation. RMPs are continually updated throughout the lifetime of the medicine as new information becomes available. More information is available under Risk-management plans.
- Post-authorisation safety studies, abbreviated as PASSs, are studies carried out after a medicine has been authorised to obtain further information on its safety, or to measure the effectiveness of risk-management measures. The PRAC assesses the protocols (aspects related to the organisation of a study) and the results of PASSs. More information can be found under Post-authorisation safety studies (PASS).
- Referrals are procedures used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral related to safety of medicines, the PRAC is requested by a Member State or the European Commission to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. More information can be found under Referral procedures.
Ongoing referrals
|
Procedure |
Status |
Update |
|---|---|---|
|
Article-31 referral: Leuprorelin-containing depot medicinal products |
Under evaluation |
PRAC continued its assessment. |
|
Article-31 referral: Ifosfamide solutions |
Under evaluation | PRAC continued its assessment. |
|
Article-31 referral: Ulipristal acetate 5mg medicinal products |
Under evaluation | PRAC continued its assessment. |